Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide + SRT + LHRHa in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer
NCT04181203Phase 3Active, not recruiting
- Sponsor
- Unicancer
- Start
- Jan 2020
- Primary completion
- Sep 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of apalutamide in prostate cancer (PCa) (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival at 5 years. Started Jan 2020; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04181203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04181203.